Bleeding from every orifice
After reviewing the earnings released by Medtronic and listening to the call the vision that came to us was a patient laying on the operating table suffering from multiple self-inflicted gunshot wounds who was bleeding from every orifice. Unfortunately for the patient a skilled surgeon was not standing at table but Bevis and Butthead. How bad is it? Domestic sales declined The company is guiding toward the lower range of growth 6...
Will this work?
Although formulary position is more critical than face to face contact with a sales rep, whenever a company launches a new drug especially one that they are betting the ranch on it’s all hands-on deck. This is the situation Novo Nordisk is about to encounter when the FDA approves the oral version of semaglutide. Yes GLP-1 usage is increasing as physicians have embraced this therapy option. However as we have...
High Stakes Poker
Doyle Brunson a living legend in the poker world once said; “The key to no-limit is to put a man to a decision for all his chips.” In the high stakes short-acting insulin market Lilly and Novo Nordisk and to some extent Sanofi currently have the best hands. However as everyone knows the best hand does not always win. With billions at stake here we’re having a difficult time figuring out...
The next Tandem
October 30, 2017 shares of Tandem closed at $2.24 yesterday shares closed at $61.91 THAT’S AN INCREASE OF 2,663.84%. That’s not astonishing that’s firkin crazy. Just by way of comparison Dexcom over that same time frame increased a very respectable 209.30%. Now we’d say a Tandem like turnaround is a once in a lifetime event but in this wacky world of ours you never know. And many have asked of...
It was the best of times, it was the worst of times
Although the famous novel by Charles Dickens A Tale of Two Cites was not set in Denmark that famous quote It was the best of times, it was the worst of times applies to what’s happening to Novo Nordisk who released results this morning. It’s the best of times because sales of GLP-1’s continue to accelerate, it’s the worst of times because insulin is now a commodity. It’s the best...
Time to deep breathe
Sometimes you realize that we are on the cusp of a structural change, a tipping point if you will. Given what we have witnessed over the past few weeks we sense that we have reached such a point when it comes to intensive and semi-intensive insulin management. The results from Abbott, Dexcom, Tandem, Insulet and even Medtronic have painted a graphic picture of the future. We’re not sure when we said...
What it all means
It’s no surprise that shares of Insulet are skyrocketing today after the release of what can only called an incredible quarter, and frankly incredible is an understatement. As outstanding as these numbers were and as positive as the future looks, we thought we’d go beyond the numbers and provide some deeper insight into not just what this means for Insulet but the insulin pump and CGM markets. So here goes...
Yep it’s as wacky as ever
A few thoughts today as our wacky world has gone off the reservation in terms of wackiness, so let’s get right to it Dexcom has a blowout quarter increases revenue guidance so naturally the stock sinks almost 5.5%. Now we get that some long time Dexcom investors are taking profits and honestly, we can’t blame them given the how shares have skyrocketed over the past year or so. And we do...
Major Happy Dance
Looking at the results announced by Tandem this afternoon we think its safe to say two things; the company has completed their transformation and the folks in Northridge should be worried, very worried. Let’s take a look at what can only be described as astonishing numbers; “Worldwide pump shipments increased 290 percent to 21,258 pumps from 5,447 pumps Sales increased 173 percent to $93.3 million from $34.1 million Operating margin improved to negative...
Nothing new here
Strong revenue growth, adding more capacity, increasing revenue guidance all in an expanding market what more could anyone want. Nothing if you’re a Dexcom investor as this company continues to methodically build their already strong business. As well as the company is doing it would be foolish to ignore what could derail this runway freight train. Here are just some of the possible items that could push this train off...